Literature DB >> 2830928

A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice.

T Kumada1, W A Dittman, P W Majerus.   

Abstract

The antithrombotic action of thrombomodulin was studied in mice. Rat and mouse thrombomodulin were isolated from lung acetone powders, and anti-rat thrombomodulin antibodies were prepared in rabbits. The antibodies neutralized both mouse (Kd approximately 150 nM) and rat thrombomodulin (Kd approximately 50 nM). A role for thrombomodulin in vivo was shown in mice injected intravenously (IV) with thrombin. All mice injected with 15 U thrombin (bolus) died of thromboembolism (mean survival 55 minutes), whereas those injected with a lower dosage survived. Prior injection with anti-rat thrombomodulin (1.8 mg IgG/mouse) potentiated the lethal effects of subsequent thrombin, whereas injection of thrombomodulin (isolated from mouse lung) prior to thrombin prolonged survival in a thrombomodulin concentration-dependent manner. The protective effect of thrombomodulin persisted for 30 minutes but after one hour thrombin injection was as toxic as in control animals. The half life (t1/2) for plasma clearance of 125I-mouse lung thrombomodulin was nine minutes. The major site of clearance was the liver, although thrombomodulin accumulated in several organs ten minutes after injection. The mechanism by which antithrombomodulin antibodies potentiated the lethal effects of thrombin was studied by measuring the protein C activating cofactor activity on vena cava removed from animals injected with antibodies. Protein C activation was inhibited by antibodies, suggesting a role for activated protein C in prevention of lethal thromboembolism. We found no effect of antibodies on the clearance of thrombin from mouse plasma, suggesting that blockade of endothelial endocytosis of thrombin does not play a significant role in the effects of antibodies. These results indicate that thrombomodulin participates in the defense against thrombosis in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830928

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Plasma thrombomodulin levels in dogs naturally infected with Leishmania infantum.

Authors:  P Ciaramella; L Cortese; M Corona; R Ambrosio; A Di Loria; A Persechino
Journal:  Vet Res Commun       Date:  2004-08       Impact factor: 2.459

2.  Up-regulation of thrombomodulin by activation of histamine H1-receptors in human umbilical-vein endothelial cells in vitro.

Authors:  K Hirokawa; N Aoki
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

3.  Recombinant and chemo-/bio-orthogonal synthesis of liposomal thrombomodulin and its antithrombotic activity.

Authors:  Lin Wang; Rui Jiang; Yang Liu; Maosheng Cheng; Qingyu Wu; Xue-Long Sun
Journal:  J Biosci Bioeng       Date:  2017-07-08       Impact factor: 2.894

4.  Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.

Authors:  W A Dittman; T Kumada; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Bio-inspired liposomal thrombomodulin conjugate through bio-orthogonal chemistry.

Authors:  Hailong Zhang; Jacob Weingart; Rui Jiang; Jianhao Peng; Qingyu Wu; Xue-Long Sun
Journal:  Bioconjug Chem       Date:  2013-03-15       Impact factor: 4.774

6.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

Review 7.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

8.  Thrombomodulin improves early outcomes after intraportal islet transplantation.

Authors:  W Cui; J T Wilson; J Wen; J Angsana; Z Qu; C A Haller; E L Chaikof
Journal:  Am J Transplant       Date:  2009-05-20       Impact factor: 8.086

9.  Thrombomodulin in intensive care patients.

Authors:  J Boldt; T Wollbrück; S Sonneborn; A Welters; G Hempelmann
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

10.  Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo.

Authors:  Ronald Carnemolla; Colin F Greineder; Ann-Marie Chacko; Kruti Rajan Patel; Bi-Sen Ding; Sergei Zaitsev; Charles T Esmon; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.